- Home
- GAU vs MNKD Comparison
GAU vs MNKD Comparison
Compare GAU & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | MNKD |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.7M | 793.6M |
| IPO Year | 2006 | 2004 |
Fundamental Metrics
Financial Performance| Metric | GAU | MNKD |
|---|---|---|
| Price | $2.43 | $2.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.08 | ★ $8.56 |
| AVG Volume (30 Days) | 2.7M | ★ 3.7M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $82.77 | $35.81 |
| Revenue Next Year | $29.09 | $11.89 |
| P/E Ratio | ★ N/A | $134.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $1.22 | $2.23 |
| 52 Week High | $3.62 | $6.51 |
Technical Indicators
Market Signals| Indicator | GAU | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 45.02 |
| Support Level | $2.38 | $2.52 |
| Resistance Level | $2.55 | $6.18 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 7.04 | 50.89 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.